Evidence map›Paper›PMID 30922362›Full record

ReviewJournal for immunotherapy of cancer2019

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.

Gaia Griguolo, Tomás Pascual, Maria Vittoria Dieci, Valentina Guarneri, Aleix Prat

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal for immunotherapy of cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. [Overexpression of CDHR2 inhibits proliferation of breast cancer cells by inhibiting the PI3K/Akt pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  20. Article

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gaia GriguoloTranslational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain.
Tomás PascualTranslational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain.
Maria Vittoria DieciDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Aleix PratTranslational Genomics and Targeted Therapeutics in Solid Tumors, IDIBAPS, Barcelona, Spain. alprat@clinic.cat.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer. In addition, HER2+ breast cancer is generally considered more immunogenic than hormone receptor-positive (HR+)/HER2-, and specific molecular HER2+ subgroups (e.g. HER2-enriched disease) are more immunogenic than others (e.g. Luminal A or B). From a clinical perspective, the immune system plays a relevant prognostic role in HER2+ breast cancer and contributes to the therapeutic effects of trastuzumab. However, as more HER2-targeted agents become available, a better understanding of the role played by the immune system in modulating therapy response to different agents will be needed. Furthermore, the recent introduction in oncology of immune checkpoint inhibitors capable of unleashing anti-tumor immune response opens new possibilities for therapeutic combinations in HER2+ breast cancer. Here, we review the current pre-clinical and clinical data on the interplay between the immune system and HER2+ breast cancer, focusing on different HER2-targeted treatments and the biological heterogeneity that exists within HER2+ disease. Finally, we discuss new therapeutic approaches exploiting the immune system to increase activity or revert resistance to HER2-targeted agents.

Indexed as

AnimalsAntineoplastic Agents, ImmunologicalBreast NeoplasmsClinical Trials as TopicDrug TherapyErb-b2 Receptor Tyrosine KinasesFemaleHumansLymphocytes, Tumor-InfiltratingMolecular Targeted TherapyNeoadjuvant TherapyAntineoplastic Agents, ImmunologicalERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerHER2Immune checkpointsImmunityTargeted treatmentTumor infiltrating lymphocytes

Identifiers

PMID30922362
PMCPMC6439986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.